B cell–ablative therapy for the treatment of autoimmune diseases

Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura

2001 • 553 citations

Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes

2001 • 523 citations

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy

2001 • 362 citations

Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: Evidence for a pathogenetic role of B cells

2002 • 255 citations

Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia

2001 • 173 citations

A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia.

2000 • 144 citations

Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-versus-Host Disease

2000 • 143 citations

Rituximab for myasthenia gravis developing after bone marrow transplant

2000 • 139 citations

B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.

2002 • 136 citations

Anti‐CD20 monoclonal antibody (Rituximab) for life‐threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus

2002 • 135 citations

Favourable response to therapy with the anti‐CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease

2001 • 111 citations

Rituxan in the Treatment of Cold Agglutinin Disease

1998 • 98 citations

Monotherapy with Rituximab Induces Rapid Remission of Recurrent Cold Agglutinin-Mediated Hemolytic Anemia in a Patient with Indolent Lympho-Plasmacytic Lymphoma

2001 • 33 citations